Halozyme Therapeutics (HALO) Tops Q2 EPS by 26c; Raises Outlook

Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.66, $0.26 better than the analyst estimate of $0.40. Revenue for the quarter came in at $136.5 million versus the consensus estimate of $103.16 million.

GUIDANCE:

Halozyme Therapeutics sees FY2021 EPS of $1.85-$2.00, versus the consensus of $1.41. Halozyme Therapeutics sees FY2021 revenue of $425-445 million, versus the consensus of $404.6 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Kroger meets earnings expectations, revenue tops estimates
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance